3q26-29 Amplification in head and neck squamous cell carcinoma: a review of established and prospective oncogenes

被引:17
作者
Davidson, Matthew A. [1 ]
Shanks, Emma J. [1 ]
机构
[1] Canc Res UK Beatson Inst, Garscube Estate,Switchback Rd, Glasgow G61 1BD, Lanark, Scotland
关键词
3q26-29; HNSCC; HPV-negative; insulin signalling; PI3K/AKT; RNA-binding protein; COMPARATIVE GENOMIC HYBRIDIZATION; RNA-BINDING PROTEIN; FACTOR-I RECEPTOR; ACTIN MESSENGER-RNA; ENDOPLASMIC-RETICULUM STRESS; TO-MESENCHYMAL TRANSITION; TUMOR-SUPPRESSOR GENES; INITIATION-FACTOR; 5A; BREAST-CANCER; CHROMOSOMAL-ABERRATIONS;
D O I
10.1111/febs.14061
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Head and neck squamous cell carcinoma (HNSCC) is significantly under-represented in worldwide cancer research, yet survival rates for the disease have remained static for over 50 years. Distant metastasis is often present at the time of diagnosis, and is the primary cause of death in cancer patients. In the absence of routine effective targeted therapies, the standard of care treatment remains chemoradiation in combination with (often disfiguring) surgery. A defining characteristic of HNSCC is the amplification of a region of chromosome 3 (3q26-29), which is consistently associated with poorer patient outcome. This review provides an overview of the role the 3q26-29 region plays in HNSCC, in terms of both known and as yet undiscovered processes, which may have potential clinical relevance.
引用
收藏
页码:2705 / 2731
页数:27
相关论文
共 254 条
  • [1] Adam MF, 1999, HEAD NECK-J SCI SPEC, V21, P146, DOI 10.1002/(SICI)1097-0347(199903)21:2<146::AID-HED8>3.0.CO
  • [2] 2-U
  • [3] Exome Sequencing of Head and Neck Squamous Cell Carcinoma Reveals Inactivating Mutations in NOTCH1
    Agrawal, Nishant
    Frederick, Mitchell J.
    Pickering, Curtis R.
    Bettegowda, Chetan
    Chang, Kyle
    Li, Ryan J.
    Fakhry, Carole
    Xie, Tong-Xin
    Zhang, Jiexin
    Wang, Jing
    Zhang, Nianxiang
    El-Naggar, Adel K.
    Jasser, Samar A.
    Weinstein, John N.
    Trevino, Lisa
    Drummond, Jennifer A.
    Muzny, Donna M.
    Wu, Yuanqing
    Wood, Laura D.
    Hruban, Ralph H.
    Westra, William H.
    Koch, Wayne M.
    Califano, Joseph A.
    Gibbs, Richard A.
    Sidransky, David
    Vogelstein, Bert
    Velculescu, Victor E.
    Papadopoulos, Nickolas
    Wheeler, David A.
    Kinzler, Kenneth W.
    Myers, Jeffrey N.
    [J]. SCIENCE, 2011, 333 (6046) : 1154 - 1157
  • [4] Alajez NM, 2012, ONCOTARGET, V3, P1641
  • [5] CCR 20th Anniversary Commentary: Preclinical Study of Proteasome Inhibitor Bortezomib in Head and Neck Cancer
    Allen, Clint T.
    Conley, Barbara
    Sunwoo, John B.
    Van Waes, Carter
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (05) : 942 - 943
  • [6] The proteasome: a novel target for cancer chemotherapy
    Almond, JB
    Cohen, GM
    [J]. LEUKEMIA, 2002, 16 (04) : 433 - 443
  • [7] [Anonymous], 2016, DATABASE
  • [8] [Anonymous], 1992, HEAD NECK SURG
  • [9] Cetuximab and bevacizumab: preclinical data and phase II trial in recurrent or metastatic squamous cell carcinoma of the head and neck
    Argiris, A.
    Kotsakis, A. P.
    Hoang, T.
    Worden, F. P.
    Savvides, P.
    Gibson, M. K.
    Gyanchandani, R.
    Blumenschein, G. R., Jr.
    Chen, H. X.
    Grandis, J. R.
    Harari, P. M.
    Kies, M. S.
    Kim, S.
    [J]. ANNALS OF ONCOLOGY, 2013, 24 (01) : 220 - 225
  • [10] Phase II Trial of Pemetrexed and Bevacizumab in Patients With Recurrent or Metastatic Head and Neck Cancer
    Argiris, Athanassios
    Karamouzis, Michalis V.
    Gooding, William E.
    Branstetter, Barton F.
    Zhong, Shilong
    Raez, Luis E.
    Savvides, Panayiotis
    Romkes, Marjorie
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1140 - 1145